Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

342 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort.
Damotte D, Warren S, Arrondeau J, Boudou-Rouquette P, Mansuet-Lupo A, Biton J, Ouakrim H, Alifano M, Gervais C, Bellesoeur A, Kramkimel N, Tlemsani C, Burroni B, Duche A, Letourneur F, Si H, Halpin R, Creasy T, Herbst R, Ren X, Morel P, Cesano A, Goldwasser F, Leroy K. Damotte D, et al. Among authors: gervais c. J Transl Med. 2019 Nov 4;17(1):357. doi: 10.1186/s12967-019-2100-3. J Transl Med. 2019. PMID: 31684954 Free PMC article.
The impact of body composition parameters on severe toxicity of nivolumab.
Hirsch L, Bellesoeur A, Boudou-Rouquette P, Arrondeau J, Thomas-Schoemann A, Kirchgesner J, Gervais C, Jouinot A, Chapron J, Giraud F, Wislez M, Alexandre J, Blanchet B, Goldwasser F. Hirsch L, et al. Among authors: gervais c. Eur J Cancer. 2020 Jan;124:170-177. doi: 10.1016/j.ejca.2019.11.003. Epub 2019 Nov 30. Eur J Cancer. 2020. PMID: 31794927
CAR T-cell Entry into Tumor Islets Is a Two-Step Process Dependent on IFNγ and ICAM-1.
Kantari-Mimoun C, Barrin S, Vimeux L, Haghiri S, Gervais C, Joaquina S, Mittelstaet J, Mockel-Tenbrinck N, Kinkhabwala A, Damotte D, Lupo A, Sibony M, Alifano M, Dondi E, Bercovici N, Trautmann A, Kaiser AD, Donnadieu E. Kantari-Mimoun C, et al. Among authors: gervais c. Cancer Immunol Res. 2021 Dec;9(12):1425-1438. doi: 10.1158/2326-6066.CIR-20-0837. Epub 2021 Oct 22. Cancer Immunol Res. 2021. PMID: 34686489
Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study.
Boudou-Rouquette P, Arrondeau J, Gervais C, Durand JP, Fabre E, De Percin S, Villeminey CV, Piketty AC, Rassy N, Ulmann G, Damotte D, Mansuet-Lupo A, Giraud F, Alifano M, Wislez M, Alexandre J, Jouinot A, Goldwasser F. Boudou-Rouquette P, et al. Among authors: gervais c. EBioMedicine. 2021 Nov;73:103630. doi: 10.1016/j.ebiom.2021.103630. Epub 2021 Oct 20. EBioMedicine. 2021. PMID: 34688030 Free PMC article.
Development and validation of a RNAseq signature for prognostic stratification in endometrial cancer.
Beinse G, Le Frere Belda MA, Just PA, Bekmezian N, Koual M, Garinet S, Leroy K, Letourneur F, Lusson A, Mulot C, Le Corre D, Metairie M, Delanoy N, Blons H, Gervais C, Durdux C, Chapron C, Goldwasser F, Terris B, Badoual C, Taly V, Laurent-Puig P, Borghese B, Bats AS, Alexandre J. Beinse G, et al. Among authors: gervais c. Gynecol Oncol. 2022 Mar;164(3):596-606. doi: 10.1016/j.ygyno.2022.01.005. Epub 2022 Jan 13. Gynecol Oncol. 2022. PMID: 35033379
Potential competing risk of death in older high-risk endometrial carcinoma patients: Results from a multicentric retrospective cohort.
Gorgeu V, Borghese B, Koual M, Just PA, Lefrere Belda MA, Delanoy N, Durdux C, Chapron C, Goldwasser F, Gervais C, Blons H, Terris B, Badoual C, Taly V, Laurent-Puig P, Bats AS, Alexandre J, Beinse G. Gorgeu V, et al. Among authors: gervais c. Gynecol Oncol. 2022 Aug;166(2):269-276. doi: 10.1016/j.ygyno.2022.05.016. Epub 2022 May 26. Gynecol Oncol. 2022. PMID: 35643579
Discovery and validation of a transcriptional signature identifying homologous recombination-deficient breast, endometrial and ovarian cancers.
Beinse G, Just PA, Le Frere Belda MA, Laurent-Puig P, Jacques S, Koual M, Garinet S, Leroy K, Delanoy N, Blons H, Gervais C, Durdux C, Chapron C, Goldwasser F, Terris B, Badoual C, Taly V, Bats AS, Borghese B, Alexandre J. Beinse G, et al. Among authors: gervais c. Br J Cancer. 2022 Oct;127(6):1123-1132. doi: 10.1038/s41416-022-01900-9. Epub 2022 Jun 25. Br J Cancer. 2022. PMID: 35752712 Free PMC article.
Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter Study.
Velev M, Puszkiel A, Blanchet B, de Percin S, Delanoy N, Medioni J, Gervais C, Balakirouchenane D, Khoudour N, Pautier P, Leary A, Ajgal Z, Hirsch L, Goldwasser F, Alexandre J, Beinse G. Velev M, et al. Among authors: gervais c. Pharmaceuticals (Basel). 2021 Aug 16;14(8):804. doi: 10.3390/ph14080804. Pharmaceuticals (Basel). 2021. PMID: 34451901 Free PMC article.
[Constipation and cancer: Current strategies].
Gervais C, Ducrotté P, Piche T, Di Palma M, Jovenin N, Scotté F. Gervais C, et al. Bull Cancer. 2016 Sep;103(9):794-804. doi: 10.1016/j.bulcan.2016.05.010. Epub 2016 Jun 21. Bull Cancer. 2016. PMID: 27341746 Review. French.
342 results